Replies to post #455010 on Anavex Life Sciences Corp (AVXL)

[crescentmotor]

What disturbs me is the fact that IMGN finally had a wholly owned approved product and each quarter sales were growing.

I totally agree with you. ARNA's drug had not received approval but it was months away and FDA approval, based on prior trials, seemed inevitable to me and that is exactly what happened not too long after the acquisition. The reality is when an acquirer comes to the target BOD and offers a no risk offer double the current stock price, it's almost always going to be game over. The acquiring companies know that so they just lay in wait until the market almost guarantees their success. My main biotech investment, other than AVXL, is in SAVA. SAVA is only six months away from completing a large AD Phase III trial and has demonstrated two years' disease stabilization in mild AD patients--unheard of results (with the caveat that much of the Phase II data was not blinded). Over 90% of the Phase III patients in two large ongoing trials have rolled over into OLE programs after completing treatment. But SAVA's capitalization is a measly $852 million due to various controversial developments I don't need to repeat for purposes of this post. Shorts have made a fortune on the stock and their obvious gameplan is to continue to suppress the stock price hoping that the first Phase III trial fails. That's how this high risk sector works.

[tredenwater2]

Why do you think Dr. Missling is trying to fold Rett Syndrome, Alzheimers MAA, starting A 3-71 Schizophrenia, lining up Parkinsons Ph 2b/3(?) imaging study partnered with MJF, Fragile X ph 2b/3……….?

I think given time most here answer their own complaints/questions from present past experiences. This is a monster pharma in the making with a precision medicine “platform” from which we will launch i to revenue building. One drug trial doesnt go right or delays or the buyout wait but from my viewpoint Dr. M and team are juggling/preparing about 6-8 trials for success. And yes one under powered Rett trial was a small unfortunate mistake but given the enormity of whats coming Im a little surprised at the “experienced” naysayers lack of vision and understanding. Its turned into a daytime soap opera with a lot of hand wringing and tissue boxes.

In conclusion I find it very unlikely that we get bought out for $20,$30, or even $100 with the way Dr Missling is preparing to “launch” into revenue. The big boys know it, Dr. Missling knows it and so the games, lawsuits, and systematic soft bashing from “shareholders” continues.

Cheers

Tred